TWI241302B - Lactam compounds and pharmaceutical use thereof - Google Patents
Lactam compounds and pharmaceutical use thereof Download PDFInfo
- Publication number
- TWI241302B TWI241302B TW090129582A TW90129582A TWI241302B TW I241302 B TWI241302 B TW I241302B TW 090129582 A TW090129582 A TW 090129582A TW 90129582 A TW90129582 A TW 90129582A TW I241302 B TWI241302 B TW I241302B
- Authority
- TW
- Taiwan
- Prior art keywords
- group
- substituent
- diabetic
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pyrrole Compounds (AREA)
Description
1241302 A8 B8 C8 D8 ___ 六、申請專利範園 1 Q ·如申請專利範圍第8項之內醯胺化合物或其製 藥學上容許之鹽,其中一般式(I )之3和1)之碳原子的 絕對配置皆爲s、C之碳原子之絕對配置爲R或S者。 1 1 · 一種輸糖增強作用劑,其特徵爲以下述一般式 (I )所示內醯胺化合物或其製藥學上容許之鹽爲有效成 分者,
〔上式中,A表示碳原子所構成單環或二環所成芳環 ’以碳’及選自氮、氧及硫之雜原子所構成5〜7員之1〜3 個環所成雜環,或碳原子所構成單環或二環所成脂環,R 2 、R3和R4可爲相同或不同,分別獨立示氫原子、鹵素原 子、羥基、碳數1〜18烷基、碳數1〜18烷氧基、碳數1〜12 院硫基、碳數1〜12院磺醯基、醯基、胺基、竣基、碳數1 〜8烷氧羰基、硝基、三氟甲基,可具有取代基之碳數1〜6 炔基,可具有取代基之以碳原子構成之碳數5〜12芳基’可 具有取代基之以碳及氮、氧、硫等構成之5〜7員之1〜3個 環所成雜芳基,可具有取代基之苯甲氧基’ B示可具有取 代基之以碳原子構成之單環或二個環所成之芳環’可具有 取代基之以碳及氮、氧、硫所等構成之5〜7員之1〜3個環 ---------------訂------Φ (請先閲·«背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) Α4規格(210Χ297公釐) -5 - 1241302 Λ8 B8 C8 D8 _ 六、申請專利範圍 所成雜環,或可具有取代基以碳原子構成之單環或二個環 所成之脂環, (請先閱讀背面之注意事項再填寫本頁) —X —係一 NH —、一 NR5 — (R5係碳數1〜6之低 級火兀基)、—S —、— C Η 2 —, 一 Υ —係—ΝΗ —、一 NR5 — (R5係碳數1〜6之低 級烷基,可具有取代基之醯基,碳數1〜8之烷氧羰基,在 氮上可具有碳數1〜6之直鏈狀或岐鏈狀或環狀之烷基之胺 甲醯基,在硫原子上可具有碳數1〜6之直鏈狀或岐鏈狀或 環狀烷基之磺醯基)、一 0 —, —Z —可爲—NH —、— CH2 —、— CR6r7_ ( R6示氫原子、R7爲可具有取代基之碳數1〜18之烷基), —W —不—NRi —、或一CR8r9—(式中,Ri示氫原 子,可具有取代基之碳數丨〜6低級烷基,R 8、R 9示氫原 子),a、b、c分別示碳原子之位置, 但是, (i )上述取代基係選自鹵素原子、羥基、烷基、院 氧基、烷硫基、醯基、胺基、烷氧羰基、三氟甲基、芳基 所構成群〕。 經濟部智慧財產局員工消費合作社印製 1 2 ·如申請專利範圍第1 1項之輸糖增強作用劑, 其中一般式(I )中,A示芳環、雜環或脂環,R2、r3 和R4可爲相同或不同構造,分別獨立示氫原子、鹵素原子 、經基、院基、院氧基、院硫基、垸磺醯基、醯基、胺基 、羧基、院氧擬基、硝基、三氟甲基,可具有取代基之芳 基’可具有取代基之雜芳基,可具有取代基之苯甲氧基, 本紙張;d逋用中@國家標準(CNS ) ( 21GX297公釐) — 1241302 A8 B8 C8 D8 六、申請專利範圍 可具有取代基之芳環,可具有取代基之雜環,或可具 有取代基之脂環, ^ X -係—N Η -、— N R 5 — ( R 5係低級烷基)— S —、一 C Η 2 —, —γ〜係—ΝΗ —、— NR5— (R5係低級烷基,可具有 取代基之醯基、烷氧羰基、胺甲醯基、磺醯基)、-〇- —z —可爲—NH —、— CH2 —、— CR6R7 —(尺6係 氫原子、R7爲可具有取代基之碳數1〜18之烷基),一 w —示—NR1—或—CR8R9 —(式中,R1示氫原子,可 具有取代基之碳數1〜6低級烷基,R 8、R 9分別示氫原子 )° 1 3 · —種糖輸送增強作用劑,其特徵爲以如申請專 利範圍第1項〜第1 〇項中任一項之內醯胺化合物或其製 藥學上容許之鹽爲有效成分者。 1 4 · 一種降血糖劑,其特徵爲以如申請專利範圍第 1項〜第1 2項中任一項之內醯胺化合物或其製藥學上容 許之鹽爲有效成分者。 1 5 · —種糖尿病、糖尿病性末梢神經障礙、糖尿病 性腎症、糖尿病性網膜症、糖尿病性大血管症、耐糖能異 常症或肥胖症之預防和/或治療劑,其特徵爲以如申請專 利範圍第1項〜第1 2項中任一項之內醯胺化合物或其製 藥學上容許之鹽爲有效成分者。 本紙張尺度適用中國國家榇準(CNS ) A4規格(210X297公釐) ---------ΛΨ—I (請先閲讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000367175 | 2000-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI241302B true TWI241302B (en) | 2005-10-11 |
Family
ID=18837660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW090129582A TWI241302B (en) | 2000-12-01 | 2001-11-29 | Lactam compounds and pharmaceutical use thereof |
Country Status (26)
Country | Link |
---|---|
US (3) | US7153850B2 (zh) |
EP (1) | EP1346993B1 (zh) |
JP (2) | JP3826400B2 (zh) |
KR (1) | KR100826818B1 (zh) |
CN (2) | CN1269818C (zh) |
AT (1) | ATE446297T1 (zh) |
AU (3) | AU1850202A (zh) |
BG (1) | BG107857A (zh) |
BR (1) | BR0115852A (zh) |
CA (1) | CA2430124C (zh) |
CZ (1) | CZ20031520A3 (zh) |
DE (1) | DE60140270D1 (zh) |
ES (1) | ES2331299T3 (zh) |
HU (1) | HUP0400806A3 (zh) |
IL (1) | IL156158A0 (zh) |
MX (1) | MXPA03004876A (zh) |
NO (1) | NO325401B1 (zh) |
NZ (1) | NZ526164A (zh) |
PL (1) | PL362835A1 (zh) |
RU (1) | RU2287530C2 (zh) |
SK (1) | SK6582003A3 (zh) |
TW (1) | TWI241302B (zh) |
UA (1) | UA76969C2 (zh) |
WO (1) | WO2002044180A1 (zh) |
YU (1) | YU42603A (zh) |
ZA (1) | ZA200304100B (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1269818C (zh) * | 2000-12-01 | 2006-08-16 | 味之素株式会社 | 内酰胺化合物及其药物用途 |
BRPI0407303A (pt) * | 2003-02-07 | 2006-02-07 | Ajinomoto Kk | Composição farmacêutica |
CA2544310A1 (en) * | 2003-10-31 | 2005-05-12 | Ajinomoto Co., Inc. | New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof |
WO2005068467A1 (ja) | 2004-01-14 | 2005-07-28 | Ajinomoto Co., Inc. | 新規縮環化合物 |
AU2006241684A1 (en) * | 2005-04-28 | 2006-11-09 | Ajinomoto Co., Inc. | Novel lactam compound |
WO2008126920A1 (ja) | 2007-04-11 | 2008-10-23 | Ajinomoto Co., Inc. | 糖尿病治療薬 |
WO2008139575A1 (ja) * | 2007-04-27 | 2008-11-20 | Ajinomoto Co., Inc. | 経口投与用製剤 |
WO2008139574A1 (ja) * | 2007-04-27 | 2008-11-20 | Ajinomoto Co., Inc. | ラクタム化合物の結晶形およびその製造方法 |
WO2008136394A1 (ja) * | 2007-04-27 | 2008-11-13 | Ajinomoto Co., Inc. | ラクタム化合物の製造方法及びその製造中間体 |
CN101619041B (zh) * | 2008-07-02 | 2012-07-04 | 重庆华邦制药股份有限公司 | 一种二酮基含氮环化合物的合成方法及其中间体 |
JP2012180282A (ja) * | 2009-07-02 | 2012-09-20 | Ajinomoto Co Inc | ラクタム化合物の製造方法およびその製造中間体 |
JP2012180283A (ja) * | 2009-07-02 | 2012-09-20 | Ajinomoto Co Inc | ラクタム化合物の製造方法およびその製造中間体 |
KR20170095850A (ko) * | 2014-12-22 | 2017-08-23 | 이에이 파마 가부시키가이샤 | 각막 상피 장애 치료제 |
US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
MX2021008937A (es) * | 2019-01-23 | 2021-11-12 | Glycolysis Biomed Co Ltd | Compuestos de beta-lactama o sales de los mismos para su uso en la prevencion o tratamiento de accion prolongada del trastorno del metabolismo de la glucosa. |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US189597A (en) * | 1877-04-17 | Improvement in portable wash-stands | ||
US48847A (en) * | 1865-07-18 | Improvement in vessels for reception and transportation of night-soil | ||
PT1000059E (pt) | 1997-07-30 | 2004-12-31 | Wyeth Corp | Agonistas triciclicos de vasopressina |
JP4204657B2 (ja) * | 1997-12-05 | 2009-01-07 | 有限会社ケムフィズ | 糖尿病の予防・治療剤 |
CN1269818C (zh) | 2000-12-01 | 2006-08-16 | 味之素株式会社 | 内酰胺化合物及其药物用途 |
BRPI0407303A (pt) * | 2003-02-07 | 2006-02-07 | Ajinomoto Kk | Composição farmacêutica |
-
2001
- 2001-11-29 CN CNB018223559A patent/CN1269818C/zh not_active Expired - Fee Related
- 2001-11-29 HU HU0400806A patent/HUP0400806A3/hu unknown
- 2001-11-29 AU AU1850202A patent/AU1850202A/xx active Pending
- 2001-11-29 AT AT01998549T patent/ATE446297T1/de not_active IP Right Cessation
- 2001-11-29 IL IL15615801A patent/IL156158A0/xx unknown
- 2001-11-29 BR BR0115852-0A patent/BR0115852A/pt not_active Application Discontinuation
- 2001-11-29 ES ES01998549T patent/ES2331299T3/es not_active Expired - Lifetime
- 2001-11-29 PL PL01362835A patent/PL362835A1/xx not_active Application Discontinuation
- 2001-11-29 KR KR1020037007327A patent/KR100826818B1/ko not_active IP Right Cessation
- 2001-11-29 MX MXPA03004876A patent/MXPA03004876A/es active IP Right Grant
- 2001-11-29 WO PCT/JP2001/010435 patent/WO2002044180A1/ja active IP Right Grant
- 2001-11-29 RU RU2003116126/04A patent/RU2287530C2/ru not_active IP Right Cessation
- 2001-11-29 CZ CZ20031520A patent/CZ20031520A3/cs unknown
- 2001-11-29 YU YU42603A patent/YU42603A/sh unknown
- 2001-11-29 DE DE60140270T patent/DE60140270D1/de not_active Expired - Lifetime
- 2001-11-29 CA CA2430124A patent/CA2430124C/en not_active Expired - Fee Related
- 2001-11-29 AU AU2002218502A patent/AU2002218502B2/en not_active Ceased
- 2001-11-29 JP JP2002546550A patent/JP3826400B2/ja not_active Expired - Lifetime
- 2001-11-29 EP EP01998549A patent/EP1346993B1/en not_active Expired - Lifetime
- 2001-11-29 NZ NZ526164A patent/NZ526164A/en unknown
- 2001-11-29 TW TW090129582A patent/TWI241302B/zh not_active IP Right Cessation
- 2001-11-29 UA UA2003055026A patent/UA76969C2/uk unknown
- 2001-11-29 CN CN200610095903A patent/CN100577651C/zh not_active Expired - Fee Related
- 2001-11-29 SK SK658-2003A patent/SK6582003A3/sk unknown
-
2003
- 2003-05-27 ZA ZA200304100A patent/ZA200304100B/en unknown
- 2003-05-28 NO NO20032439A patent/NO325401B1/no not_active IP Right Cessation
- 2003-05-29 BG BG107857A patent/BG107857A/bg unknown
- 2003-06-02 US US10/449,774 patent/US7153850B2/en not_active Expired - Fee Related
-
2006
- 2006-04-06 US US11/398,675 patent/US7326701B2/en not_active Expired - Fee Related
- 2006-05-12 JP JP2006134026A patent/JP4505753B2/ja not_active Expired - Fee Related
- 2006-11-24 AU AU2006241377A patent/AU2006241377B2/en not_active Ceased
-
2007
- 2007-11-30 US US11/948,288 patent/US7632830B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI241302B (en) | Lactam compounds and pharmaceutical use thereof | |
CA2516370C (en) | A process of preparing imatinib and imatinib prepared thereby | |
CA2958095C (en) | 2-(2,4,5-substituted aniline) pyrimidine derivative, pharmaceutical composition and use thereof | |
Adams et al. | Pyrimidinylimidazole inhibitors of p38: cyclic N-1 imidazole substituents enhance p38 kinase inhibition and oral activity | |
AU2005335298C1 (en) | N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof | |
JP3819024B2 (ja) | 置換ピリミジン化合物およびその使用 | |
CA2613303A1 (en) | An oxime derivative for use as a glucokinase activator | |
CA2771775A1 (en) | Compounds and compositions as protein kinase inhibitors | |
CA2474104A1 (en) | N-oxides of n-phenyl-2-pyrimidine-amine derivatives | |
ATE303387T1 (de) | Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus | |
MX2010006182A (es) | Derivados de isoxazolo-piridazina. | |
RS20080191A (en) | Pyrazole derivatives and their medical use | |
AR035722A1 (es) | Derivados de indol, procesos para su preparacion, composiciones farmaceuticas que los comprenden y el uso de dichos compuestos para la produccion de medicamentos | |
TWI262917B (en) | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same | |
MY143578A (en) | Piperazinediones as oxytocin receptor antagonists | |
UA70966C2 (uk) | Піримідини, що інгібують реплікацію віл | |
RS65704A (en) | Aza-arylpiperazines | |
CA2412941A1 (en) | Piperidine compounds for use as ccr-3 inhibitors | |
JP2006213732A5 (zh) | ||
PE20060771A1 (es) | Profarmaco de amida de gemcitabina y composiciones que lo contienen | |
IL291590B1 (en) | Novel modified quinoline-8-carbonitrile compounds with androgen receptor unblocking activity and their uses | |
CA2635093A1 (en) | Derivatives of sulindac, use thereof and preparation thereof | |
CA2462903A1 (en) | Beta-lactamyl vasopressin v1a antagonists | |
CA2438524A1 (en) | Cyclopropaheterocycles as non-nucleoside reverse transcriptase inhibitors | |
CA2531484A1 (en) | Novel bioisosteres of actinonin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |